DOCSLIB.ORG

COVID-19 Overview of Information Available to Support The

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
COVID-19 Overview of Information Available to Support The COVID-19 Overview of information available to support the development of medical countermeasures and interventions against COVID-19 This document is conceived as a living document, to be updated on a weekly basis. It is based on open-access publications (scientific journals and preprint databases, communications by WHO, health authorities and companies) in English language. Please note that the present version has not been submitted to any peer-review process. Any comment / addition that can help improve the contents of this review will be most welcome. For navigation through the various sections, please click on the headings of the table of contents and follow the links marked in blue in the document. Authors: Martine Denis, Valerie Vandeweerd, Diane Van der Vliet Paper version: dd. 23 MAR 2020 Transdisciplinary Insights - Living Paper | 1 Contents List of abbreviations .......................................................................................................................................................... 6 Introduction ...................................................................................................................................................................... 7 The virus ............................................................................................................................................................................ 7 Coronaviruses ............................................................................................................................................................... 7 SARS-CoV-2 is a betacoronavirus of bat origin ............................................................................................................. 8 Genome structure ......................................................................................................................................................... 9 Sequence diversity among isolates ............................................................................................................................. 10 Phylogenetics .............................................................................................................................................................. 10 Sequence homology of the S gene .............................................................................................................................. 12 Structure of S and interactions with the ACE2 receptor ............................................................................................. 12 Other SARS-CoV-2 genes ............................................................................................................................................. 14 Immune responses to SARS-CoV-2 infection .................................................................................................................. 14 First observations in COVID-19 patients ..................................................................................................................... 14 Antigens and epitopes ................................................................................................................................................ 15 Epitope predictions ................................................................................................................................................. 15 Cross-reactivity ....................................................................................................................................................... 17 Antibody response ...................................................................................................................................................... 17 Clinical disease ................................................................................................................................................................ 17 Initial observations in Wuhan ..................................................................................................................................... 17 Incubation period ........................................................................................................................................................ 17 Description of clinical disease ..................................................................................................................................... 18 Clinical disease in China .......................................................................................................................................... 18 Clinical disease outside China ................................................................................................................................. 20 Clinical imaging ........................................................................................................................................................... 21 Laboratory finding & biomarkers ................................................................................................................................ 23 Virus load ................................................................................................................................................................ 23 Cell counts ............................................................................................................................................................... 24 Biochemistry ........................................................................................................................................................... 24 Coagulation parameters.......................................................................................................................................... 25 Time from illness onset to death ................................................................................................................................ 26 Case fatality rate ......................................................................................................................................................... 26 Case fatality rate in China ....................................................................................................................................... 26 Case fatality rate outside China .............................................................................................................................. 27 Authors: Martine Denis, Valerie Vandeweerd, Diane Van der Vliet Paper version: dd. 23 MAR 2020 Transdisciplinary Insights - Living Paper | 2 Special populations ..................................................................................................................................................... 28 Older men, cancer and immunocompromised patients ......................................................................................... 28 Children ................................................................................................................................................................... 28 Pregnancy and newborns ........................................................................................................................................ 30 Case definition ............................................................................................................................................................ 32 Definition of severe disease .................................................................................................................................... 32 Pathophysiology of COVID-19 ......................................................................................................................................... 33 Viral tropism ................................................................................................................................................................ 33 Determinants of pathogenicity ................................................................................................................................... 34 S protein and interaction with ACE2 ....................................................................................................................... 34 Infection of immune cells? ...................................................................................................................................... 34 Signs of liver injury .................................................................................................................................................. 35 Other observations ................................................................................................................................................. 35 Antibody-dependent enhancement of infection? ...................................................................................................... 35 Pathological observations from biopsies and autopsies............................................................................................. 35 Acute respiratory distress syndrome .......................................................................................................................... 36 Co-infections ............................................................................................................................................................... 37 Animal models ................................................................................................................................................................ 38 Transgenic mice
Load more

Recommended publications
  • Clinical Characteristics and Risk Factors for Developed COVID-19 Patients Transferring to Designated Hospital from Jianghan Fang
    medRxiv preprint doi: https://doi.org/10.1101/2020.04.21.20074724; this version posted April 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Clinical Characteristics and Risk factors for developed COVID-19 patients transferring to designated hospital from Jianghan Fangcang shelter Hospital: a retrospective, observational study 1Yunfei Liao#, 2Yong Feng #, 3Bo Wang#, 1Hanyu Wang, 4Jinsha Huang, 5Yaxin Wu, 1Ziling Wu, 1Xiao Chen, 6Chao Yang, 7Xinqiao Fu and 1Hui Sun 1Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China (Y Liao MD PhD, H Wang MD, Z Wu MD, X Chen MD, H Sun MD); 2Department of Orthopedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China (Y Feng MD PhD); 3Department of Rehabilitation, Wuhan No.1 Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China (B Wang MD); 4Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China (J Huang MD PhD); 5First Clinical College, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China (Y Wu BD) 6Department of Vascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China (C Yang MD PhD); 7Outpatient Department, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China (X Fu PhD) # Contributed equally Correspondence to Hui Sun MD, Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China Email: [email protected] 1 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
    [Show full text]
  • Care of Pediatric Patients During COVID-19 Pandemic
    Care of Pediatric Patients during COVID-19 Pandemic Wuhan United “Living Through A Pandemic” Series 4 Co-organized with: Department of Pediatrics, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Forti & Consevage, P.C., Pennsylvania, USA Mead Johnson Nutrition, USA MEDICAL DISCLAIMER THIS PRESENTATION IS FOR EDUCATIONAL AND INFORMATIONAL PURPOSES ONLY AND MAY NOT BE CONSTRUED AS MEDICAL ADVICE. THE INFORMATION IS NOT INTENDED TO REPLACE MEDICAL ADVICE OFFERED BY PHYSICIANS. Contents 1. Opening remarks: Dr. Runming Jin 2. Diagnosis, Treatment and Prevention of COVID-19 in Children: Dr. Xiaoyan Wu 3. Management of Wards of Pediatric Hematological-Malignancy during COVID-19: Dr. Xiaoyan Wu 4. Protection for Medical Staff: Dr. Lei Li 5. Management of Children with other Non-COVID 19 related Health Care Needs: Dr. Lei Li Opening Remarks Runming Jin Clinical Professor, Department Chair Department of Pediatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Diagnosis, Treatment and Prevention of COVID-19 in Children Xiaoyan Wu MD, PhD, Associate Professor Department of Pediatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Information of Pediatric Patients in China • 2143 pediatric patients with COVID-19 were reported to the Chinese Center for Disease Control and Prevention from January 16 to February 8, 2020 • 731 (34.1%) laboratory-confirmed cases and 1412 (65.9%) suspected cases. • 1213 cases (56.6%) were boys. The age of disease onset ranged from 1.5m to 17y. • The median time from illness onset to diagnoses was 2 days (range: 0 to 42 days). • Of the 2143 pediatric patients, only one child died.
    [Show full text]
  • Annual Report 2020 03 Corporate Information
    Our Vision Dedicate to become a first-tier enterprise in the global mainstream pharmaceutical and healthcare market. Our Mission Better health for families worldwide. 02 Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Contents 04 Corporate Information 07 Financial Highlights 08 Chairman’s Statement 12 Management Discussion and Analysis 67 Five-Year Statistics 68 Report of the Directors 91 Supervisory Committee Report 93 Corporate Governance Report 104 Environmental, Social and Governance Report 135 Biographical Details of Directors, Supervisors and Senior Management 144 Independent Auditor’s Report 149 Consolidated Statement of Profit or Loss 150 Consolidated Income Statement 151 Consolidated Statement of Financial Position 153 Consolidated Statement of Changes in Equity 155 Consolidated Statement of Cash Flows 157 Notes to Financial Statements 276 Definitions Annual Report 2020 03 Corporate Information Directors Authorized Representatives Executive Director Mr. Wu Yifang (吳以芳)11 Mr. Wu Yifang (吳以芳) Ms. Kam Mei Ha Wendy (甘美霞) (Chairman1 and Chief Executive Officer) Mr. Chen Qiyu (陳啟宇)12 Non-executive Directors Strategic Committee Mr. Chen Qiyu (陳啟宇)2 Mr. Chen Qiyu (陳啟宇) (Chairman) Mr. Yao Fang (姚方)3 Mr. Wu Yifang (吳以芳) Mr. Xu Xiaoliang (徐曉亮) Mr. Yao Fang (姚方) Mr. Gong Ping (龔平)4 Mr. Xu Xiaoliang (徐曉亮) Mr. Pan Donghui (潘東輝)4 Ms. Li Ling (李玲) Mr. Zhang Houlin (張厚林)5 Mr. Liang Jianfeng (梁劍峰)6 Audit Committee Mr. Wang Can (王燦)7 Ms. Mu Haining (沐海寧)9 Mr. Tang Guliang (湯谷良) (Chairman) Mr. Jiang Xian (江憲) Independent Non-executive Directors Mr. Gong Ping (龔平)4 Mr. Jiang Xian (江憲) Mr. Wang Can (王燦)7 Dr. Wong Tin Yau Kelvin (黃天祐) Ms.
    [Show full text]
  • A Collaborative Online AI Engine for CT-Based COVID-19 Diagnosis
    medRxiv preprint doi: https://doi.org/10.1101/2020.05.10.20096073; this version posted May 19, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license . 1 A collaborative online AI engine for CT-based COVID-19 diagnosis 2 3 Yongchao Xu1,2#, Liya Ma1#, Fan Yang3#, Yanyan Chen4#, Ke Ma2, Jiehua Yang2, Xian Yang2, Yaobing 4 Chen 5, Chang Shu2, Ziwei Fan2, Jiefeng Gan2, Xinyu Zou2, Renhao Huang2, Changzheng Zhang6, 5 Xiaowu Liu6, Dandan Tu6, Chuou Xu1, Wenqing Zhang2, Dehua Yang7, Ming-Wei Wang7, Xi Wang8, 6 Xiaoliang Xie8, Hongxiang Leng9, Nagaraj Holalkere10, Neil J. Halin10, Ihab Roushdy Kamel11, Jia Wu12, 7 Xuehua Peng13, Xiang Wang14, Jianbo Shao13, Pattanasak Mongkolwat15, Jianjun Zhang16,17, Daniel L. 8 Rubin18, Guoping Wang 5, Chuangsheng Zheng3*, Zhen Li1*,Xiang Bai2*, Tian Xia2,5* 9 1Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and 10 Technology, Wuhan 430030, China. 11 2School of Electronic Information and Communications, Huazhong University of Science and Technology, Wuhan 12 430074, China. 13 3Department of Radiology, Union Hospital of Tongji Medical College, Huazhong University of Science and 14 Technology, Wuhan 430022, China. 15 4Department of Information Management, Tongji Hospital, Huazhong University of Science and Technology, 16 Wuhan 430030, China. 17 5Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 18 Wuhan 430030, China. 19 6HUST-HW Joint Innovation Lab, Wuhan 430074, China.
    [Show full text]
  • Social Media and China's Virus Outbreak
    Volume 18 | Issue 14 | Number 6 | Article ID 5418 | Jul 15, 2020 The Asia-Pacific Journal | Japan Focus Social Media and China's Virus Outbreak Anonymous China rules the world” (2009). In an interview Abstract: In the early stage of the coronavirus with the state media CCTV, Jacques praised the outbreak in China, social media were bursting Chinese government’s crisis management with anger and desperation. Many pleaded for capacity in the wake of the pandemic, saying medical help, called for public attention to the that this, “can be a historic moment where unattended and asked for accountability for people come to see what the strengths of the local officials who failed to respond to the Chinese system are.” (Tuwen Ouni 2020) public health crisis in time. But with the epicenter shifting to Europe and NorthThis marked a dramatic turnaround from the America, a series of social media tactics, early stages of the pandemic when there was highlighting China’s successful containment speculation about whether the Chinese efforts, while disparaging foreign countries’ government’s legitimacy might be undermined responses, and spinning the origin of the by the pandemic. Public opinion in China on the coronavirus outbreak, facilitated a nationalist government’s handling of the crisis has also takeover of social media sites in China. experienced a rollercoaster ride, dipping to the bottom in early February and gradually recovering as the pandemic was contained. The state emerged from the crisis stronger than How China rewrites the narrative of the ever, trumpeting that it had led the Chinese coronavirus pandemic on social media people to victory in the war against COVID-19.
    [Show full text]
  • ERJ-00544-2020.Shareable
    ORIGINAL ARTICLE | INFECTIOUS DISEASE Nosocomial outbreak of COVID-19 pneumonia in Wuhan, China Xiaorong Wang1,12, Qiong Zhou 1,12, Yukun He2,12, Lingbo Liu3, Xinqian Ma2, Xiaoshan Wei1, Nanchuan Jiang4, Limei Liang1, Yali Zheng5, Ling Ma6,YuXu2, Dong Yang7, Jianchu Zhang1, Bohan Yang1, Ning Jiang2, Tao Deng8, Bingbing Zhai8, Yang Gao8, Wenxuan Liu8, Xinghua Bai8, Tao Pan8, Guoqing Wang8, Yujun Chang 9,10, Zhi Zhang9,10, Huanzhong Shi 11, Wan-Li Ma1,13 and Zhancheng Gao2,13 Affiliations: 1Dept of Respiratory and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. 2Dept of Respiratory and Critical Care Medicine, Peking University People’s Hospital, Beijing, China. 3School of Urban Design, Wuhan University, Wuhan, China. 4Dept of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. 5Dept of Respiratory, Critical Care, and Sleep Medicine, Xiang’an Hospital of Xiamen University, Xiamen, China. 6Dept of Clinical Laboratory, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. 7Dept of Anaesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. 8Beijing CapitalBio Medical Laboratory, Beijing, China. 9National Engineering Research Center for Beijing Biochip Technology, Beijing, China. 10CapitalBio Corporation, Beijing, China. 11Dept of Respiratory and Critical Care Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China. 12Equal contributors. 13These authors are joint principal authors. Correspondence: Zhancheng Gao, Dept of Respiratory and Critical Care Medicine, Peking University People’s Hospital, Beijing 100044, China. E-mail: [email protected] @ERSpublications SARS-CoV-2 can be rapidly transmitted from person to person in nosocomial and social settings, despite patients having no symptoms https://bit.ly/34BHtB5 Cite this article as: Wang X, Zhou Q, He Y, et al.
    [Show full text]
  • World Vision China Provided Most Needed Medical Equipment to Hospitals in Wuhan City
    World Vision China Provided Most Needed Medical Equipment to Hospitals in Wuhan City In March 2020, World Vision China provided 84 sets of most needed medical equipment to 3 key hospitals in Wuhan City of Hubei Province, to assist them in fighting against novel coronavirus, after learning their needs. The donation was made through China Charity Federation, under the guidance of the Medical Management Service Guidance Center, National Health Commission. The medial equipment included 30 bilevel positive airway pressure ventilators, 30 respiratory humidifiers and 24 ECG monitors, which were respectively received by 3 key hospitals: Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, West Campus of Wuhan Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Renmin Hospital of Wuhan University. Equipment would be put into service once finishing setting up. The Medical Management Service Guidance Center of the National Health Commission provided the specifications of the needed medical equipment and connected World Vision to the hospitals with the most needs. The Commission even sent staff to the hospitals to guide the receiving and usage of the equipment. “We must ensure hospitals have what patients need to survive as well as providing families with the means and knowledge to protect themselves from the spread of this potentially deadly virus," said World Vision China National Director, John Teng. To provide support for local departments in epidemic
    [Show full text]
  • THBS4/Integrin Α2 Axis Mediates BM-Mscs Promote Angiogenesis of Gastric Cancer Associated with Chronic Helicobacter Pylori Infection
    THBS4/Integrin α2 axis mediates BM-MSCs promote angiogenesis of gastric cancer associated with chronic Helicobacter pylori infection LingNan He Wuhan Union Hospital https://orcid.org/0000-0002-0760-9789 WeiJun Wang Wuhan Union Hospital HuiYing Shi Wuhan Union Hospital Chen Jiang Wuhan Union Hospital HaiLing Yao Wuhan Union Hospital YuRui Zhang Wuhan Union Hospital Wei Qian Wuhan Union Hospital Rong Lin ( [email protected] ) Wuhan Union Hospital Research Keywords: Bone marrow-derived mesenchymal stem cells (BM-MSCs), Helicobacter Pylori, Gastric cancer (GC), Tumor angiogenesis, THBS4, Integrin α2, PI3K/AKT pathway Posted Date: April 3rd, 2021 DOI: https://doi.org/10.21203/rs.3.rs-366308/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/27 Abstract Background BM-MSCs contribute to Helicobacter pylori (H. pylori)-induced gastric cancer, but its mechanism is still unclear. The aim of our study is to investigate the specic role and mechanism of BM-MSCs in H. pylori- induced gastric cancer. Main methods Mice were received total bone marrow transplantations and then infected with H. pylori. BM-MSCs were extracted and transplanted to gastric serosal layer of mice infected with H. pylori chronically. Hematoxylin and eosin staining, immunohistochemistry staining and immunouorescence were performed to detect the tumor growth and angiogenesis in mice stomach tissues. Chicken chorioallantoic membrane assay, xenograft tumor model, and Human umbilical vein endothelial cells tube formation assay were used for in vivo and in vitro angiogenesis study. THBS4 was screened out from RNA-SEQ Analysis with gastric tissues of BM-MSCs transplantation into H.
    [Show full text]
  • Epidemiological,Clinical and Radiological Ndings in Medical Staff with COVID-19 in Wuhan, China
    Epidemiological,clinical and radiological ndings in medical staff with COVID-19 in Wuhan, China: a single-centered, retrospective cohort study Jie Liu Wuhan Union Hospital Liu Ouyang Wuhan Union Hospital Pi Guo Shantou University Medical College Haisheng Wu Shantou University Medical College Peng Fu Huazhong University of Science and Technology Yuliang Chen Shantou University Medical College Dan Yang Wuhan Union Hospital Xiaoyu Han Wuhan Union Hospital Yukun Cao Wuhan Union Hospital Osamah Alwalid Wuhan Union Hospital Hanping Wu University of Michigan Medical School Heshui Shi Wuhan Union Hospital Fan Yang Wuhan Union Hospital Yu Hu Wuhan Union Hospital Chuansheng Zheng ( [email protected] ) Huazhong University of Science and Technology Page 1/25 Research Keywords: COVID-19, Medical staff, Infectious disease, Epidemiology, Clinical features, Computerized tomography Posted Date: May 18th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-28753/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 2/25 Abstract Backgrounds In December 2019, a pneumonia associated with the severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) emerged in Wuhan city, China. As of 20 Feb 2020, a total of 2,055 medical staff infected with SARS-Cov-2 in China had been reported. The predominant cause of the infection and the failure of protection among medical staff remains unclear. We sought to explore the epidemiological, clinical characteristics and prognosis of novel coronavirus-infected medical staff. Methods Medical staff who infected with SARS-Cov-2 and admitted to Union Hospital, Wuhan between 16 Jan, 2020 to 25 Feb, 2020 were included retrospectively.
    [Show full text]
  • Managements of 13 Emergency Cardiac Surgeries Under COVID-19 Pandemic in a Sentinel Hospital
    6669 Original Article Managements of 13 emergency cardiac surgeries under COVID-19 pandemic in a Sentinel Hospital Xingjian Hu#^, Yin Wang#, Jiahong Xia, Nianguo Dong, Jiawei Shi Department of Cardiovascular Surgery, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China Contributions: (I) Conception and design: X Hu, J Shi; (II) Administrative support: J Xia, N Dong; (III) Provision of study materials or patients: N Dong, J Shi; (IV) Collection and assembly of data: X Hu, Y Wang; (V) Data analysis and interpretation: X Hu, Y Wang; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. #These authors contributed equally to this work as co-first authors. Correspondence to: Nianguo Dong, MD, PhD; Jiawei Shi, MD, PhD. Department of Cardiovascular Surgery, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Avenue 1277#, Wuhan 430000, China. Email: [email protected]; [email protected]. Background: The pneumonia outbreak caused by the 2019 novel coronavirus disease (COVID-19) creates many challenges for the healthcare sector. Currently, little is known of how the pandemic has impacted patients with cardiovascular disease. The primary focus of this study was to determine whether emergency cardiovascular surgeries can be carried out safely during the COVID-19 pandemic. Methods: Between 17 January 2020 and 11 February 2020, 13 patients were admitted to Wuhan Union Hospital for emergency cardiovascular surgery. During this time, Wuhan was a COVID-19 epicenter, and Wuhan Union Hospital is a sentinel hospital located in this area. These patients’ epidemiological histories, clinical records, laboratory assessments, imaging findings, and surgical outcomes were retrospectively reviewed.
    [Show full text]
  • Clinical E Cacy of Ribavirin in Adults Hospitalized with Severe Covid-19
    Clinical Ecacy of Ribavirin in Adults Hospitalized With Severe Covid-19: A Retrospective Analysis of 208 Patients Wei-Jing Gong Wuhan Union Hospital Tao Zhou Wuhan Union Hospital San-Lan Wu Wuhan Union Hospital Jia-Long Ye Wuhan Union Hospital Jia-Qiang Xu Wuhan Union Hospital Fang Zeng Wuhan Union Hospital Yu-Yong Su Wuhan Union Hospital Yong Han Wuhan Union Hospital Yong-Ning Lv Wuhan Union Hospital Yu Zhang ( [email protected] ) Wuhan Union Hospital https://orcid.org/0000-0003-3630-9002 Xue-Feng Cai Wuhan Union Hospital Research Keywords: Ribavirin, COVID-19, SARS-CoV-2 Posted Date: June 30th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-38021/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/12 Abstract Background: Coronavirus disease-2019 (COVID-19) spreads rapidly throughout the world. So far, no therapeutics have yet been proven to be effective. Ribavirin was recommended for the treatment of COVID-19 because of its in vitro activity. However, evidence supporting its clinical use with good ecacy is still lacking. Methods: A total of 208 conrmed severe or critical COVID-19 patients who were hospitalized in Wuhan Union West Campus between 1 February 2020 and 10 March 2020 were enrolled in the retrospective study. Patients were divided into two groups based on the use of ribavirin. The primary endpoint was the time to clinical improvement. The secondary endpoints included mortality, survival time, time to throat swab SARS-CoV-2 nucleic acid negative conversion, and hospital duration. Results: 68 patients were treated with ribavirin while 140 not.
    [Show full text]
  • 2020.03.09.20033118V1.Full.Pdf
    medRxiv preprint doi: https://doi.org/10.1101/2020.03.09.20033118; this version posted March 13, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Epidemiological, Clinical Characteristics and Outcome of Medical Staff Infected with COVID-19 in Wuhan, China: A Retrospective Case Series Analysis Authors Jie Liu 1, 2, †, Liu Ouyang 3, †, Pi Guo 4, †, Haisheng Wu 4, †, Peng Fu 5, †, Yuliang Chen 4, Dan Yang 6, Xiaoyu Han 1, 2, Yukun Cao 1, 2, Osamah Alwalid 1, 2, Juan Tao 1, 2, Shuyi Peng 1, 2, Heshui Shi 1, 2, Fan Yang 1, 2, *, Chuansheng Zheng 1, 2, * 1 Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China 2 Hubei Province Key Laboratory of Molecular Imaging, Wuhan, Hubei, China 3 Department of Orthopaedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China 4 Department of Preventive Medicine, Shantou University Medical College, Shantou, Guangdong, China 5 Department of Thyroid and Breast Surgery, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China; 6 Department of Respiratory and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China † These authors contributed equally in this work. Email: Jie Liu ([email protected]); Liu Ouyang ([email protected]); Pi Guo ([email protected]); Haisheng Wu ([email protected]); Peng Fu ([email protected]); Yuliang Chen ([email protected]); Dan Yang ([email protected]); Xiaoyu Han ([email protected]); Yukun Cao ([email protected]); Osamah Alwalid ([email protected]); Juan NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
    [Show full text]